Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128) (HELIOS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00424268
First received: January 18, 2007
Last updated: October 24, 2016
Last verified: September 2016
Results First Received: March 17, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Roflumilast
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Roflumilast Roflumilast 500 µg, once daily, oral and tiotropium 18 µg, once daily, inhaled
Placebo Placebo, once daily, oral and tiotropium 18 µg, once daily, inhaled

Participant Flow:   Overall Study
    Roflumilast   Placebo
STARTED   371 [1]   372 [1] 
COMPLETED   309   333 
NOT COMPLETED   62   39 
[1] Includes all randomized patients who took at least one dose of the investigational drug.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Roflumilast Roflumilast 500 µg, once daily, oral and tiotropium 18 µg, once daily, inhaled
Placebo Placebo, once daily, oral and tiotropium 18 µg, once daily, inhaled
Total Total of all reporting groups

Baseline Measures
   Roflumilast   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 371   372   743 
Age 
[Units: Years]
Mean (Standard Deviation)
 64.2  (9.1)   64.0  (9.3)   64.1  (9.2) 
Gender 
[Units: Participants]
     
Female   109   105   214 
Male   262   267   529 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)   [ Time Frame: Change from baseline over 24 weeks of treatment ]

2.  Secondary:   Post-bronchodilator FEV1   [ Time Frame: Change from baseline over 24 weeks of treatment ]

3.  Secondary:   COPD Exacerbation Rate (Moderate or Severe)   [ Time Frame: 24 weeks treatment period ]

4.  Secondary:   Transition Dyspnea Index (TDI) Focal Score   [ Time Frame: Change from baseline over 24 weeks of treatment ]

5.  Secondary:   Shortness of Breath Questionnaire (SOBQ) Total Score   [ Time Frame: Change from baseline over 24 weeks of treatment ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame 24 weeks treatment period
Additional Description The Safety Set was based on all randomized patients who took at least one dose of the investigational drug after randomization. Three patients randomized to placebo received roflumilast instead and were included in the roflumilast group for safety analyses.

Reporting Groups
  Description
Roflumilast Roflumilast 500 µg, once daily, oral and tiotropium 18 µg, once daily, inhaled
Placebo Placebo, once daily, oral and tiotropium 18 µg, once daily, inhaled

Serious Adverse Events
    Roflumilast   Placebo
Total, serious adverse events     
# participants affected / at risk   22/374 (5.88%)   21/369 (5.69%) 
Blood and lymphatic system disorders     
Anaemia † 1     
# participants affected / at risk   1/374 (0.27%)   1/369 (0.27%) 
# events   1   1 
Lymphoid tissue hyperplasia † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
Cardiac disorders     
Angina pectoris † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Atrioventricular block complete † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Cardiac failure † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Myocardial infarction † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Ventricular tachycardia † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Eye disorders     
Retinal artery embolism † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
Gastrointestinal disorders     
Haematochezia † 1     
# participants affected / at risk   2/374 (0.53%)   0/369 (0.00%) 
# events   2   0 
Colitis † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
Colonic polyp † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
Duodenal ulcer † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
Gastric ulcer † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
Inguinal hernia † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
General disorders     
Chest pain † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
Hepatobiliary disorders     
Bile duct stone † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
Infections and infestations     
Appendicitis † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Perianal abscess † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
Pneumonia † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Injury, poisoning and procedural complications     
Contusion † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Post procedural myocardial infarction † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Spinal compression fracture † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
Investigations     
Weight decreased † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
Musculoskeletal and connective tissue disorders     
Metatarsalgia † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Neoplasms benign, malignant and unspecified (incl cysts and polyps)     
B-cell lymphoma † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Bladder cancer † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
Meningioma † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Metastatic neoplasm † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Non-small cell lung cancer † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
Pancreatic neoplasm † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Nervous system disorders     
Cerebral ischaemia † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Cerebrovascular accident † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
Guillain-Barre syndrome † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
Psychiatric disorders     
Confusional state † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Renal and urinary disorders     
Renal failure chronic † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Respiratory, thoracic and mediastinal disorders     
Chronic obstructive pulmonary disease † 1     
# participants affected / at risk   4/374 (1.07%)   5/369 (1.36%) 
# events   4   5 
Pneumothorax † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
Pulmonary fibrosis † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Sleep apnoea syndrome † 1     
# participants affected / at risk   0/374 (0.00%)   1/369 (0.27%) 
# events   0   1 
Surgical and medical procedures     
Vascular operation † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
Vascular disorders     
Aortic aneurysm † 1     
# participants affected / at risk   1/374 (0.27%)   0/369 (0.00%) 
# events   1   0 
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA (11.0)




  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information